(Q36582692)

English

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

scientific article published on September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

infectious diseases

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Society of Infectious Diseases Pharmacists

4

object named as

Society of Infectious Diseases Pharmacists

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

George L. Drusano

3

object named as

George L Drusano

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

author name string

Thomas P Lodise

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Ben M Lomaestro

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1320-1332

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacodynamics of cefepime in patients with Gram-negative infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

BACTERIOSTATIC AND LYTIC ACTIONS OF PENICILLIN ON SENSITIVE AND RESISTANT STAPHYLOCOCCI.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1320

21 January 2018

Identifiers

10.1592/PHCO.26.9.1320

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36582692&oldid=2144417375"